Clinical Trial Search

Primary: Perimenstrual Change in Daily Adult Suicidal Ideation Questionnaire (ASIQ) Scores — .178; -.051 Mean Score Change — p=<.001

Primary: Correlation Between Objective Patient Measures (Steps, Distance Travelled, From Apple Watch) and Patient-Reported Outcome Measures (SF-36, EQ-5D, PROMIS, NDI, ODI)…

Primary: Progression-free Survival — 10.5; 11.8 Months

Primary: Brief Pain Inventory (BPI) Pain Severity Score — 5.75; 4.36; 3.89 units on a scale

Primary: Area Under the Concentration-time Curve of BI 1015550 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 2290; 2740; 3000…

Primary: Primary Performance: Rate of Participants With Successful BD Spinal NRFit™ Needle Placement in the Subarachnoid Location — 100; 46; 146 Participants

Primary: Percentage of Participants Who Have a Clinical Response to Treatment (Objective Tumor Regression) — 27.5; 27.1; 19.6; 37.5 Percentage of participants

Primary: SISI Fidelity — 80 Percentage of SISI practices implemented

Primary: Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-Years…

Primary: Rate of Relapse — .11; .13 Proportion of Participants

Primary: Change in Pain Numerical Rating Scale (Averaged Over Past 24 Hours) — -3.38; -2.30 score on a scale — p=0.057

Primary: Collection of Head Motion Data to be Used in Developing Head Stabilization Methods in Brain Radiation Patients — 95 % of time within tolerance

Primary: Change in End-expiratory Lung Impedance From Baseline Measured by Electrical Impedance Tomography (EIT) — 9; 74; 132; 7 Change in EELI (arbitrary units)

Primary: Part I: Maximum Tolerated Dose (MTD) of Ezabenlimab — NA Milligram

Primary: Maximum Observed Drug Concentration (Cmax) of Vonoprazan — 6.11; 5.81; 5.46; 5.72 nanogram per milliliter (ng/mL)